Achtung!! Imclone explodiert gerade!!!!! - 500 Beiträge pro Seite
eröffnet am 02.06.03 13:36:47 von
neuester Beitrag 02.06.03 14:39:45 von
neuester Beitrag 02.06.03 14:39:45 von
Beiträge: 3
ID: 738.460
ID: 738.460
Aufrufe heute: 0
Gesamt: 591
Gesamt: 591
Aktive User: 0
Top-Diskussionen
| Titel | letzter Beitrag | Aufrufe |
|---|---|---|
| vor 1 Stunde | 3591 | |
| vor 1 Stunde | 2691 | |
| vor 9 Minuten | 1897 | |
| vor 1 Stunde | 1799 | |
| vor 18 Minuten | 1429 | |
| vor 9 Minuten | 1345 | |
| vor 1 Stunde | 1080 | |
| vor 1 Stunde | 980 |
Meistdiskutierte Wertpapiere
| Platz | vorher | Wertpapier | Kurs | Perf. % | Anzahl | ||
|---|---|---|---|---|---|---|---|
| 1. | 1. | 17.706,42 | -0,26 | 197 | |||
| 2. | 2. | 138,74 | -1,42 | 109 | |||
| 3. | 7. | 6,6420 | -1,28 | 96 | |||
| 4. | 5. | 0,1785 | -3,25 | 70 | |||
| 5. | 8. | 3,7750 | +0,94 | 66 | |||
| 6. | 4. | 2.383,90 | +0,19 | 60 | |||
| 7. | 9. | 12,420 | +0,73 | 44 | |||
| 8. | 17. | 7,2800 | -0,34 | 37 |
Feedback
Das wird heute der Renner!!!
schon 20% vorbörslich!!!
ImClone, Genentech Soar on Drug Data
Monday June 2, 8:34 am ET
NEW YORK (Reuters) - Shares of ImClone Systems Inc. (NasdaqNM:IMCLE - News) and Genentech Inc. (NYSE
NA - News) rose sharply in pre-market trading on Monday after the companies reported positive data on experimental colon cancer drugs, boosting chances the treatments will get approved.
ADVERTISEMENT
AMERITRADE SPECIAL OFFER
· 30 commission-free trades
Start trading on us
· Command center screen
Get this FREE service
· Our 10-Second Guarantee
(restrictions apply)
Start getting your share with us
Open your account now
Genentech reported on Sunday that colon cancer patients on its Avastin drug combined with a standard therapy survived an average of 20.3 months, compared with 15.6 months for patients on the standard therapy alone. Shares rose 10 percent to $69 in pre-market trading, up from a closing price of $62.61 on Friday.
Merrill Lynch raised its 2004 earnings estimate for Genentech based on the Avastin data, and Deutsche Bank raised its price target for Genentech`s stock.
Also on Sunday, ImClone`s European partner disclosed strong data on ImClone`s experimental cancer drug Erbitux.
Shares jumped 22 percent in electronic trading before the market opened, on top of a 27 percent increase last week in anticipation of the data to be presented at an annual meeting of the American Society of Clinical Oncologists (News).
Results of a phase III trial conducted by Germany`s Merck KGaA (XETRA:MRCG.DE - News) showed that 23 percent of colorectal cancer patients taking Erbitux in combination with a standard chemotherapy treatment experienced a 50 percent reduction in tumor size, compared with about 11 percent of patients taking Erbitux alone.
Analysts expect ImClone to submit the drug to the U.S. Food and Drug Administration (News - Websites) for approval in combination with chemotherapy.
The results validate at least some of the claims originally made for the drug by Samuel Waksal, ImClone`s former chief executive. Waksal was charged with insider trading after the company`s original Erbitux marketing application was rejected by U.S. regulators in December 2001, which sent company`s stock into a tailspin.
Shares traded at $34.75 in pre-market trading on Instinet, up from a closing price of $28.50 on Friday.
The last time ImClone`s stock traded above $30 was in March of last year.
Monday June 2, 8:34 am ET
NEW YORK (Reuters) - Shares of ImClone Systems Inc. (NasdaqNM:IMCLE - News) and Genentech Inc. (NYSE
NA - News) rose sharply in pre-market trading on Monday after the companies reported positive data on experimental colon cancer drugs, boosting chances the treatments will get approved.ADVERTISEMENT
AMERITRADE SPECIAL OFFER
· 30 commission-free trades
Start trading on us
· Command center screen
Get this FREE service
· Our 10-Second Guarantee
(restrictions apply)
Start getting your share with us
Open your account now
Genentech reported on Sunday that colon cancer patients on its Avastin drug combined with a standard therapy survived an average of 20.3 months, compared with 15.6 months for patients on the standard therapy alone. Shares rose 10 percent to $69 in pre-market trading, up from a closing price of $62.61 on Friday.
Merrill Lynch raised its 2004 earnings estimate for Genentech based on the Avastin data, and Deutsche Bank raised its price target for Genentech`s stock.
Also on Sunday, ImClone`s European partner disclosed strong data on ImClone`s experimental cancer drug Erbitux.
Shares jumped 22 percent in electronic trading before the market opened, on top of a 27 percent increase last week in anticipation of the data to be presented at an annual meeting of the American Society of Clinical Oncologists (News).
Results of a phase III trial conducted by Germany`s Merck KGaA (XETRA:MRCG.DE - News) showed that 23 percent of colorectal cancer patients taking Erbitux in combination with a standard chemotherapy treatment experienced a 50 percent reduction in tumor size, compared with about 11 percent of patients taking Erbitux alone.
Analysts expect ImClone to submit the drug to the U.S. Food and Drug Administration (News - Websites) for approval in combination with chemotherapy.
The results validate at least some of the claims originally made for the drug by Samuel Waksal, ImClone`s former chief executive. Waksal was charged with insider trading after the company`s original Erbitux marketing application was rejected by U.S. regulators in December 2001, which sent company`s stock into a tailspin.
Shares traded at $34.75 in pre-market trading on Instinet, up from a closing price of $28.50 on Friday.
The last time ImClone`s stock traded above $30 was in March of last year.
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 197 | ||
| 109 | ||
| 96 | ||
| 70 | ||
| 66 | ||
| 60 | ||
| 44 | ||
| 37 | ||
| 36 | ||
| 35 |
| Wertpapier | Beiträge | |
|---|---|---|
| 35 | ||
| 30 | ||
| 28 | ||
| 26 | ||
| 25 | ||
| 24 | ||
| 22 | ||
| 21 | ||
| 20 | ||
| 17 |
